Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails Article Swipe
Laibah Arshad Khan
,
Bilal Alam
,
Naresh Kumar Ladhwani
,
H. Abid
,
Zaroon Mazhar
,
Saim Umar Gondal
,
Jawria Tufail
,
Ahmed Zia
,
Syeda Naqvi
,
Muhammad Usama Saeed
,
Zain Ul Abideen
,
Vishaka Sahjwani
,
Om Kumar Lohana
,
V. Siva Kumar
,
Saiyad Ali
,
Zainab Amjad
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1159/000546265
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1159/000546265
Background: Tenapanor is currently seen as a promising treatment for hyperphosphatemia in haemodialysis patients. Although previous meta-analysis has investigated its efficacy and safety, the potential impact of tenapanor remained a topic of further investigation. This meta-analysis aims to provide an updated and thorough assessment of tenapanor efficacy in reducing serum phosphate levels and its safety in haemodialysis patients, integrating new evidence and refining the analysis of treatment outcomes. Methodology: In this systematic review and meta-analysis, we searched online databases up to August 2024 for studies evaluating the efficacy and safety of tenapanor in haemodialysis patients. Only short-term randomized controlled trials (4 to 8 weeks) comparing tenapanor with placebo were included. The primary outcome was the change in serum phosphate levels from baseline. Safety was assessed based on data regarding drug-related adverse effects (AEs), including diarrhoea and other gastrointestinal AEs. Results: Among the selected 8 clinical trails with a total of 1001 patients, tenapanor showed a significant reduction in serum phosphate levels from baseline compared to placebo (mean difference [MD] -1.39mg/dl, 95% CI: -1.94,0.84, p <0.0001). Greater number of patients in the tenapanor group were able to achieve target serum phosphate levels of ≦5.5 mg/dl (relative risk [RR] 2.80; 95% CI: 1.70, 4.61; p < 0.0001). Drug related AEs, gastrointestinal AEs and diarrhoea was more severe in tenapanor group compared to placebo. Conclusion: In summary, the results indicate that tenapanor effectively lowers serum phosphate levels in haemodialysis patients and facilitates achievement of target levels, although drug-related side effects were common. However, these findings are based exclusively on short-term trials (4-8 weeks). Further long-term studies are needed to confirm the sustained efficacy and safety of tenapanor.
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.1159/000546265
- https://karger.com/ajn/article-pdf/doi/10.1159/000546265/4401644/000546265.pdf
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4412163079
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4412163079Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1159/000546265Digital Object Identifier
- Title
-
Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trailsWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-07-09Full publication date if available
- Authors
-
Laibah Arshad Khan, Bilal Alam, Naresh Kumar Ladhwani, H. Abid, Zaroon Mazhar, Saim Umar Gondal, Jawria Tufail, Ahmed Zia, Syeda Naqvi, Muhammad Usama Saeed, Zain Ul Abideen, Vishaka Sahjwani, Om Kumar Lohana, V. Siva Kumar, Saiyad Ali, Zainab AmjadList of authors in order
- Landing page
-
https://doi.org/10.1159/000546265Publisher landing page
- PDF URL
-
https://karger.com/ajn/article-pdf/doi/10.1159/000546265/4401644/000546265.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://karger.com/ajn/article-pdf/doi/10.1159/000546265/4401644/000546265.pdfDirect OA link when available
- Concepts
-
Medicine, Hyperphosphatemia, Meta-analysis, Hemodialysis, Randomized controlled trial, Intensive care medicine, Term (time), Internal medicine, Kidney disease, Physics, Quantum mechanicsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4412163079 |
|---|---|
| doi | https://doi.org/10.1159/000546265 |
| ids.doi | https://doi.org/10.1159/000546265 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40633530 |
| ids.openalex | https://openalex.org/W4412163079 |
| fwci | 0.0 |
| type | review |
| title | Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | 20 |
| biblio.first_page | 1 |
| topics[0].id | https://openalex.org/T10516 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9980999827384949 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2727 |
| topics[0].subfield.display_name | Nephrology |
| topics[0].display_name | Parathyroid Disorders and Treatments |
| topics[1].id | https://openalex.org/T10554 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9901999831199646 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Hemoglobinopathies and Related Disorders |
| topics[2].id | https://openalex.org/T13966 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9800999760627747 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2712 |
| topics[2].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[2].display_name | Neurological and metabolic disorders |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8962129354476929 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2776036575 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8237811326980591 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1641062 |
| concepts[1].display_name | Hyperphosphatemia |
| concepts[2].id | https://openalex.org/C95190672 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7210451364517212 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q815382 |
| concepts[2].display_name | Meta-analysis |
| concepts[3].id | https://openalex.org/C2778063415 |
| concepts[3].level | 2 |
| concepts[3].score | 0.7042314410209656 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q391744 |
| concepts[3].display_name | Hemodialysis |
| concepts[4].id | https://openalex.org/C168563851 |
| concepts[4].level | 2 |
| concepts[4].score | 0.619528591632843 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[4].display_name | Randomized controlled trial |
| concepts[5].id | https://openalex.org/C177713679 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5673671364784241 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[5].display_name | Intensive care medicine |
| concepts[6].id | https://openalex.org/C61797465 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4656437635421753 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1188986 |
| concepts[6].display_name | Term (time) |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4095648527145386 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C2778653478 |
| concepts[8].level | 2 |
| concepts[8].score | 0.3128868341445923 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1054718 |
| concepts[8].display_name | Kidney disease |
| concepts[9].id | https://openalex.org/C121332964 |
| concepts[9].level | 0 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q413 |
| concepts[9].display_name | Physics |
| concepts[10].id | https://openalex.org/C62520636 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q944 |
| concepts[10].display_name | Quantum mechanics |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8962129354476929 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/hyperphosphatemia |
| keywords[1].score | 0.8237811326980591 |
| keywords[1].display_name | Hyperphosphatemia |
| keywords[2].id | https://openalex.org/keywords/meta-analysis |
| keywords[2].score | 0.7210451364517212 |
| keywords[2].display_name | Meta-analysis |
| keywords[3].id | https://openalex.org/keywords/hemodialysis |
| keywords[3].score | 0.7042314410209656 |
| keywords[3].display_name | Hemodialysis |
| keywords[4].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[4].score | 0.619528591632843 |
| keywords[4].display_name | Randomized controlled trial |
| keywords[5].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[5].score | 0.5673671364784241 |
| keywords[5].display_name | Intensive care medicine |
| keywords[6].id | https://openalex.org/keywords/term |
| keywords[6].score | 0.4656437635421753 |
| keywords[6].display_name | Term (time) |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.4095648527145386 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/kidney-disease |
| keywords[8].score | 0.3128868341445923 |
| keywords[8].display_name | Kidney disease |
| language | en |
| locations[0].id | doi:10.1159/000546265 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S106979888 |
| locations[0].source.issn | 0250-8095, 1421-9670 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0250-8095 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | American Journal of Nephrology |
| locations[0].source.host_organization | https://openalex.org/P4310317820 |
| locations[0].source.host_organization_name | Karger Publishers |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310317820 |
| locations[0].license | |
| locations[0].pdf_url | https://karger.com/ajn/article-pdf/doi/10.1159/000546265/4401644/000546265.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | American Journal of Nephrology |
| locations[0].landing_page_url | https://doi.org/10.1159/000546265 |
| locations[1].id | pmid:40633530 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | American journal of nephrology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40633530 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5113390230 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Laibah Arshad Khan |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Laibah Arshad Khan |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5023876055 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Bilal Alam |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Bakhtawara Alam |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5109817907 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Naresh Kumar Ladhwani |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Naresh Kumar Ladhwani |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5113021709 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | H. Abid |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Hamna Abid |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5031875470 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Zaroon Mazhar |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Zain Mazhar |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5118888958 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Saim Umar Gondal |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Saim Umar Gondal |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5118888959 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Jawria Tufail |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Jawria Tufail |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5080381834 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-6907-3070 |
| authorships[7].author.display_name | Ahmed Zia |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Ahmed Zia |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5112314039 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Syeda Naqvi |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Syeda Zil e Zehra Naqvi |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5015877427 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-3326-3937 |
| authorships[9].author.display_name | Muhammad Usama Saeed |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Muhammad Usama Saeed |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5043125610 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-2395-0178 |
| authorships[10].author.display_name | Zain Ul Abideen |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Zain Ui Abideen |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5118888956 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Vishaka Sahjwani |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Vishaka Sahjwani |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5118888957 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Om Kumar Lohana |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Om Kumar Lohana |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5111334457 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | V. Siva Kumar |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Varoon Kumar |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5114157004 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Saiyad Ali |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Saiyad Ali |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5000812754 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-2270-2172 |
| authorships[15].author.display_name | Zainab Amjad |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | Zainab Amjad |
| authorships[15].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://karger.com/ajn/article-pdf/doi/10.1159/000546265/4401644/000546265.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-07-10T00:00:00 |
| display_name | Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: a systematic review and meta-analysis of short term randomized control trails |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10516 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9980999827384949 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2727 |
| primary_topic.subfield.display_name | Nephrology |
| primary_topic.display_name | Parathyroid Disorders and Treatments |
| related_works | https://openalex.org/W4296216889, https://openalex.org/W2418307134, https://openalex.org/W3145214337, https://openalex.org/W2041704983, https://openalex.org/W2072718197, https://openalex.org/W2146648131, https://openalex.org/W2908850563, https://openalex.org/W2954857069, https://openalex.org/W2125743647, https://openalex.org/W2009081188 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1159/000546265 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S106979888 |
| best_oa_location.source.issn | 0250-8095, 1421-9670 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0250-8095 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | American Journal of Nephrology |
| best_oa_location.source.host_organization | https://openalex.org/P4310317820 |
| best_oa_location.source.host_organization_name | Karger Publishers |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310317820 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://karger.com/ajn/article-pdf/doi/10.1159/000546265/4401644/000546265.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | American Journal of Nephrology |
| best_oa_location.landing_page_url | https://doi.org/10.1159/000546265 |
| primary_location.id | doi:10.1159/000546265 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S106979888 |
| primary_location.source.issn | 0250-8095, 1421-9670 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0250-8095 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | American Journal of Nephrology |
| primary_location.source.host_organization | https://openalex.org/P4310317820 |
| primary_location.source.host_organization_name | Karger Publishers |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310317820 |
| primary_location.license | |
| primary_location.pdf_url | https://karger.com/ajn/article-pdf/doi/10.1159/000546265/4401644/000546265.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | American Journal of Nephrology |
| primary_location.landing_page_url | https://doi.org/10.1159/000546265 |
| publication_date | 2025-07-09 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.8 | 102, 143 |
| abstract_inverted_index.a | 6, 29, 147, 154 |
| abstract_inverted_index.p | 173, 202 |
| abstract_inverted_index.(4 | 100 |
| abstract_inverted_index.In | 69, 222 |
| abstract_inverted_index.an | 39 |
| abstract_inverted_index.as | 5 |
| abstract_inverted_index.in | 11, 47, 55, 92, 116, 157, 179, 215, 234 |
| abstract_inverted_index.is | 2 |
| abstract_inverted_index.of | 26, 31, 44, 65, 90, 149, 177, 191, 240, 272 |
| abstract_inverted_index.on | 126, 255 |
| abstract_inverted_index.to | 37, 80, 101, 164, 185, 219, 265 |
| abstract_inverted_index.up | 79 |
| abstract_inverted_index.we | 75 |
| abstract_inverted_index.95% | 170, 198 |
| abstract_inverted_index.AEs | 209 |
| abstract_inverted_index.CI: | 171, 199 |
| abstract_inverted_index.The | 110 |
| abstract_inverted_index.and | 21, 41, 52, 61, 73, 88, 135, 210, 237, 270 |
| abstract_inverted_index.are | 252, 263 |
| abstract_inverted_index.for | 9, 83 |
| abstract_inverted_index.has | 17 |
| abstract_inverted_index.its | 19, 53 |
| abstract_inverted_index.new | 59 |
| abstract_inverted_index.the | 23, 63, 86, 114, 141, 180, 224, 267 |
| abstract_inverted_index.was | 113, 123, 212 |
| abstract_inverted_index.< | 203 |
| abstract_inverted_index.(4-8 | 258 |
| abstract_inverted_index.1001 | 150 |
| abstract_inverted_index.2024 | 82 |
| abstract_inverted_index.AEs, | 207 |
| abstract_inverted_index.AEs. | 138 |
| abstract_inverted_index.Drug | 205 |
| abstract_inverted_index.Only | 95 |
| abstract_inverted_index.This | 34 |
| abstract_inverted_index.[MD] | 168 |
| abstract_inverted_index.[RR] | 196 |
| abstract_inverted_index.able | 184 |
| abstract_inverted_index.aims | 36 |
| abstract_inverted_index.data | 127 |
| abstract_inverted_index.from | 120, 161 |
| abstract_inverted_index.more | 213 |
| abstract_inverted_index.risk | 195 |
| abstract_inverted_index.seen | 4 |
| abstract_inverted_index.side | 245 |
| abstract_inverted_index.that | 227 |
| abstract_inverted_index.this | 70 |
| abstract_inverted_index.were | 108, 183, 247 |
| abstract_inverted_index.with | 106, 146 |
| abstract_inverted_index.(mean | 166 |
| abstract_inverted_index.1.70, | 200 |
| abstract_inverted_index.2.80; | 197 |
| abstract_inverted_index.4.61; | 201 |
| abstract_inverted_index.Among | 140 |
| abstract_inverted_index.based | 125, 253 |
| abstract_inverted_index.group | 182, 217 |
| abstract_inverted_index.mg/dl | 193 |
| abstract_inverted_index.other | 136 |
| abstract_inverted_index.serum | 49, 117, 158, 188, 231 |
| abstract_inverted_index.these | 250 |
| abstract_inverted_index.topic | 30 |
| abstract_inverted_index.total | 148 |
| abstract_inverted_index.(AEs), | 132 |
| abstract_inverted_index.August | 81 |
| abstract_inverted_index.Safety | 122 |
| abstract_inverted_index.change | 115 |
| abstract_inverted_index.impact | 25 |
| abstract_inverted_index.levels | 51, 119, 160, 190, 233 |
| abstract_inverted_index.lowers | 230 |
| abstract_inverted_index.needed | 264 |
| abstract_inverted_index.number | 176 |
| abstract_inverted_index.online | 77 |
| abstract_inverted_index.review | 72 |
| abstract_inverted_index.safety | 54, 89, 271 |
| abstract_inverted_index.severe | 214 |
| abstract_inverted_index.showed | 153 |
| abstract_inverted_index.target | 187, 241 |
| abstract_inverted_index.trails | 145 |
| abstract_inverted_index.trials | 99, 257 |
| abstract_inverted_index.weeks) | 103 |
| abstract_inverted_index.≦5.5 | 192 |
| abstract_inverted_index.Further | 260 |
| abstract_inverted_index.Greater | 175 |
| abstract_inverted_index.achieve | 186 |
| abstract_inverted_index.adverse | 130 |
| abstract_inverted_index.common. | 248 |
| abstract_inverted_index.confirm | 266 |
| abstract_inverted_index.effects | 131, 246 |
| abstract_inverted_index.further | 32 |
| abstract_inverted_index.levels, | 242 |
| abstract_inverted_index.outcome | 112 |
| abstract_inverted_index.placebo | 107, 165 |
| abstract_inverted_index.primary | 111 |
| abstract_inverted_index.provide | 38 |
| abstract_inverted_index.related | 206 |
| abstract_inverted_index.results | 225 |
| abstract_inverted_index.safety, | 22 |
| abstract_inverted_index.studies | 84, 262 |
| abstract_inverted_index.updated | 40 |
| abstract_inverted_index.weeks). | 259 |
| abstract_inverted_index.0.0001). | 204 |
| abstract_inverted_index.Although | 14 |
| abstract_inverted_index.However, | 249 |
| abstract_inverted_index.Results: | 139 |
| abstract_inverted_index.although | 243 |
| abstract_inverted_index.analysis | 64 |
| abstract_inverted_index.assessed | 124 |
| abstract_inverted_index.baseline | 162 |
| abstract_inverted_index.clinical | 144 |
| abstract_inverted_index.compared | 163, 218 |
| abstract_inverted_index.efficacy | 20, 46, 87, 269 |
| abstract_inverted_index.evidence | 60 |
| abstract_inverted_index.findings | 251 |
| abstract_inverted_index.indicate | 226 |
| abstract_inverted_index.patients | 178, 236 |
| abstract_inverted_index.placebo. | 220 |
| abstract_inverted_index.previous | 15 |
| abstract_inverted_index.reducing | 48 |
| abstract_inverted_index.refining | 62 |
| abstract_inverted_index.remained | 28 |
| abstract_inverted_index.searched | 76 |
| abstract_inverted_index.selected | 142 |
| abstract_inverted_index.summary, | 223 |
| abstract_inverted_index.thorough | 42 |
| abstract_inverted_index.(relative | 194 |
| abstract_inverted_index.Tenapanor | 1 |
| abstract_inverted_index.baseline. | 121 |
| abstract_inverted_index.comparing | 104 |
| abstract_inverted_index.currently | 3 |
| abstract_inverted_index.databases | 78 |
| abstract_inverted_index.diarrhoea | 134, 211 |
| abstract_inverted_index.included. | 109 |
| abstract_inverted_index.including | 133 |
| abstract_inverted_index.long-term | 261 |
| abstract_inverted_index.outcomes. | 67 |
| abstract_inverted_index.patients, | 57, 151 |
| abstract_inverted_index.patients. | 13, 94 |
| abstract_inverted_index.phosphate | 50, 118, 159, 189, 232 |
| abstract_inverted_index.potential | 24 |
| abstract_inverted_index.promising | 7 |
| abstract_inverted_index.reduction | 156 |
| abstract_inverted_index.regarding | 128 |
| abstract_inverted_index.sustained | 268 |
| abstract_inverted_index.tenapanor | 27, 45, 91, 105, 152, 181, 216, 228 |
| abstract_inverted_index.treatment | 8, 66 |
| abstract_inverted_index.assessment | 43 |
| abstract_inverted_index.controlled | 98 |
| abstract_inverted_index.difference | 167 |
| abstract_inverted_index.evaluating | 85 |
| abstract_inverted_index.randomized | 97 |
| abstract_inverted_index.short-term | 96, 256 |
| abstract_inverted_index.systematic | 71 |
| abstract_inverted_index.tenapanor. | 273 |
| abstract_inverted_index.-1.39mg/dl, | 169 |
| abstract_inverted_index.-1.94,0.84, | 172 |
| abstract_inverted_index.Background: | 0 |
| abstract_inverted_index.Conclusion: | 221 |
| abstract_inverted_index.achievement | 239 |
| abstract_inverted_index.effectively | 229 |
| abstract_inverted_index.exclusively | 254 |
| abstract_inverted_index.facilitates | 238 |
| abstract_inverted_index.integrating | 58 |
| abstract_inverted_index.significant | 155 |
| abstract_inverted_index.<0.0001). | 174 |
| abstract_inverted_index.Methodology: | 68 |
| abstract_inverted_index.drug-related | 129, 244 |
| abstract_inverted_index.investigated | 18 |
| abstract_inverted_index.haemodialysis | 12, 56, 93, 235 |
| abstract_inverted_index.meta-analysis | 16, 35 |
| abstract_inverted_index.investigation. | 33 |
| abstract_inverted_index.meta-analysis, | 74 |
| abstract_inverted_index.gastrointestinal | 137, 208 |
| abstract_inverted_index.hyperphosphatemia | 10 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 16 |
| citation_normalized_percentile.value | 0.3324783 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |